Literature DB >> 23460390

[Interleukin-1-mediated diseases].

D Holzinger1, H Becker, A M Jacobi.   

Abstract

Interleukin-1 (IL-1)-mediated diseases are caused by an inappropriately high production and release of IL-1 beta which results in a multitude of symptoms, e.g. arthritis, exanthema, conjunctivitis, serositis, fever and loss of hearing. If IL-1-mediated diseases remain unrecognized or are recognized and treated too late, long-term complications, such as amyloidosis may occur. In recent years the diagnostic and therapeutic options with respect to IL-1-mediated diseases have drastically improved. These diseases often manifesting in childhood can now be treated with monoclonal antibodies against IL-1 or with IL-1 receptor antagonists. Increased IL-1 secretion does not only play a role in relatively rare hereditary diseases, such as cryopyrin-associated periodic fever syndromes or familial Mediterranean fever but also in widespread diseases, such as gout or type 2 diabetes. This article will focus on pathogenic, diagnostic and therapeutic aspects of IL-1-mediated inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23460390     DOI: 10.1007/s00108-012-3186-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  31 in total

1.  The cutaneous manifestations in children with familial Mediterranean fever (recurrent hereditary polyserositis). A six-year study.

Authors:  H A Majeed; Z Quabazard; Z Hijazi; S Farwana; F Harshani
Journal:  Q J Med       Date:  1990-06

2.  Preliminary criteria for classification of adult Still's disease.

Authors:  M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

3.  On a Form of Chronic Joint Disease in Children.

Authors:  G F Still
Journal:  Med Chir Trans       Date:  1897

4.  Still's disease in the adult.

Authors:  E G Bywaters
Journal:  Ann Rheum Dis       Date:  1971-03       Impact factor: 19.103

5.  Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1.

Authors:  F S Di Giovine; S E Malawista; G Nuki; G W Duff
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

6.  Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.

Authors:  H Ralph Schumacher; Robert R Evans; Kenneth G Saag; James Clower; William Jennings; Steven P Weinstein; George D Yancopoulos; Jian Wang; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

7.  Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.

Authors:  Susannah D Brydges; James L Mueller; Matthew D McGeough; Carla A Pena; Amirhossein Misaghi; Chhavi Gandhi; Chris D Putnam; David L Boyle; Gary S Firestein; Anthony A Horner; Pejman Soroosh; Wendy T Watford; John J O'Shea; Daniel L Kastner; Hal M Hoffman
Journal:  Immunity       Date:  2009-06-04       Impact factor: 31.745

8.  Epidemiology and outcome of adult-onset Still's disease in Northern Norway.

Authors:  K J Evensen; H C Nossent
Journal:  Scand J Rheumatol       Date:  2006 Jan-Feb       Impact factor: 3.641

9.  Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis.

Authors:  Ebun Omoyinmi; Raja Hamaoui; Anne Pesenacker; Kiran Nistala; Halima Moncrieffe; Simona Ursu; Lucy R Wedderburn; Patricia Woo
Journal:  Rheumatology (Oxford)       Date:  2012-07-05       Impact factor: 7.580

10.  Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Authors:  Nicolino Ruperto; Hermine I Brunner; Pierre Quartier; Tamás Constantin; Nico Wulffraat; Gerd Horneff; Riva Brik; Liza McCann; Ozgur Kasapcopur; Lidia Rutkowska-Sak; Rayfel Schneider; Yackov Berkun; Inmaculada Calvo; Muferet Erguven; Laurence Goffin; Michael Hofer; Tilmann Kallinich; Sheila K Oliveira; Yosef Uziel; Stefania Viola; Kiran Nistala; Carine Wouters; Rolando Cimaz; Manuel A Ferrandiz; Berit Flato; Maria Luz Gamir; Isabelle Kone-Paut; Alexei Grom; Bo Magnusson; Seza Ozen; Flavio Sztajnbok; Karine Lheritier; Ken Abrams; Dennis Kim; Alberto Martini; Daniel J Lovell
Journal:  N Engl J Med       Date:  2012-12-20       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.